^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:PT217 (CD47 inhibitor, DLL3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PRNewswire
    Title:

    Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA

    Published date:
    04/08/2024
    Excerpt:
    ...U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.